AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01760876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coronary intervention
Description: The BioFreedom drug coated stent (DCS) Coronary Stent Delivery System is comprised of three key components
Study NCT02731950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate and Bupivacaine 0.125%
Description: Each patient will receive bupivacaine 0.125% with 5% magnesium sulphate by infusion through a catheter used for epidural analgesia, positioned presternal.
Study NCT03209336 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy by Intrabeam（Zeiss Meditech，Jena，Germany）
Description: We confirmed that if the patients had the distant metastasis before IORT. The median radiation dose was 5.00 Gy (range: 5.00-10.00Gy), the average dose was 6.00 Gy. The median radiation time was 0:33:24 (range: 0:21:45-1:06:23), which was the same with the patients'. All patients' surface dose ranged from 15.00 to 28.50 Gy.
Study NCT03829566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
Study NCT03829566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A medication used as chemotherapy and to suppress the immune system
Study NCT03829566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
Study NCT03829566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rATG
Description: A rabbit polyclonal antibody to lymphocytes
Study NCT03829566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: A corticosteroid medication used to suppress the immune system and decrease inflammation
Study NCT03829566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
Study NCT03829566 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVIg
Description: Pooled immunoglobulin (IgG) from thousands of plasma donors that has immunomodulatory and anti-inflammatory effects
Study NCT03829566 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cells
Description: Infusion of patient's own stem cells
Study NCT02619578 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: TEAS
Description: According to the theory of traditional Chinese medicine, bilateral Baihui (GV20), Yingtang (EX-HN3), Zusanli (ST36) and Neiguan (PC6) were chosen as the acupuncture points. These acupoints were identified according to the traditional anatomic localization . Gel electrodes were applied to the skin after it had been cleaned with ethyl alcohol. The acupoints were then stimulated electrically with an intensity of 12-15 mA and dense-disperse frequency of 2/100 Hz for 30 min, using the Hwato electronic acupuncture treatment instrument (model No. SDZ-V, Suzhou Medical Appliances Co., Ltd, Suzhou, China). The intensity was adjusted to maintain a slight twitching of local muscles according to individual maximum tolerance, indicating a satisfactory of De-Qi phenomenon and thus adequate stimulation.
Study NCT02619578 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Con
Description: The patients in the Con group had the electrodes applied at the same acupoints, but received no stimulation.
Study NCT02619578 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: propofol, remifentanil, vecuronium
Description: Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v.
Study NCT02619578 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: mechanical ventilation
Description: Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
Study NCT02676778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7777
Study NCT01280643 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative studies
Study NCT03786536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediSieve Magnetic Haemofiltration System
Description: The MediSieve Magnetic Haemofiltration System is a medical device intended for use in extracorporeal clinical procedures to remove magnetic targets (e.g. malaria infected red blood cells) from a patient's bloodstream.
Study NCT04249817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Conferencing with Exteneded Role Practitioner (VC-ERP)
Description: Participant goes to Ontario Telemedicine site for follow-up. At site, participant will get a physical assessment by an extended role practitioner and then will connect to their rheumatologist by videoconferencing for completion of follow-up.
Study NCT01362829 — intervention group
Intervention type: OTHER
Intervention: Determined by intended physician
Description: We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
Study NCT05314907 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Explanation on how to use self-sampling device and training in the screening visit.
Description: During the screening visit, woman is offered to participate in the study. If she accepts, informed consent is signed, a sociodemographic questionnaire is collected, and a cervical sample is collected for HPV detection by the health professional in the consultation.~Then, the professional informs the woman of how to carry out the self-collection using Evalyn Brush and after the woman collects an HPV sample by self-sampling in the same medical center as a trainning.~Finally, a new cervibrush (Evalyn brush) is given to the woman for home self-sampling, together with written and picture-based instructions on how to obtain the sample and an acceptability questionnaire. After one month from the screening visit, woman is requested to return the self-collected sample together with the questionnaire in person to the recruitment centre.
Study NCT05314907 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Only explanation on how to use self-sampling device.
Description: During the screening visit, woman is offered to participate in the study. If she accepts, informed consent is signed, a sociodemographic questionnaire is collected, and a cervical sample is taken for HPV detection by the health professional in the consultation.~Then, the professional informs the woman of how to carry out the self-collection using Evalyn.~Finally, a Evalyn brush is given to the woman for home self-sampling, together with written and picture-based instructions on how to obtain the sample and an acceptability questionnaire. After one month from the screening visit, woman is requested to return the self-collected sample together with the questionnaire in person to the recruitment centre.
Study NCT02073682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: After the 5 day treatment with LMWH, patients receive edoxaban 60 mg once daily (QD) as 2 × 30 mg tablets (or 1 x 30 mg tablet QD for patients requiring dose adjustment) for the remainder of the treatment period.
Study NCT02073682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin
Description: Dalteparin was administered via subcutaneous injection at a dose of 200 IU/kg (maximum daily dose 18,000 IU) for 30 days, and at a dose of 150 IU/kg from Day 31 to the end of treatment.
Study NCT02073682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Description: Therapeutic doses of subcutaneous LMWH were administered for at least 5 days (to patients in the edoxaban group); this 5-day period may have included the pre-randomization LMWH (if applicable). The choice of parenteral LMWH was up to the treating physician.
Study NCT03077230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre/Post Test of a Lung Cancer Screening Decision Aid
Description: After completing the baseline survey, the research team member will ask each participant asked to view the lung cancer screening decision aid on a tablet. The following areas regarding lung cancer screening: What is lung cancer?, Why is lung cancer a problem?, What is screening?, What is low-dose CT screening, Recommended frequency of screening, Screening factors, lung cancer risks and benefits (magnitude of benefit, harms, false positive, invasive procedures, radiation, stress/anxiety), Summary, Values Clarification, Screening Choice, and Smoking cessation messaging for current smokers OR positive reinforcement for former smokers.
Study NCT00813189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GH treatment
Description: GH treatment will be administered at a weekly dose of 0.46 mg/kg/ week, divided into seven daily subcutaneous injections. Subcutaneous injections should be given slowly, in the thigh. In order to prevent lipoatrophy, the injection site should be varied. The injection should be given at bedtime.
Study NCT01740414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MN-166 (50 mg) First
Description: In this arm of the study participants were first maintained on 50 mg MN-166 BID for approximately 14 days, and were then switched onto placebo maintenance. The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo \& MN-166).
Study NCT01740414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo First
Description: This arm of the study participants were first maintained on placebo for approximately 14 days, and were then switched onto 50mg MN-166 BID maintenance. . The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo \& MN-166).
Study NCT04475120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal lactoferrin
Description: oral and intra-nasal formulation
Study NCT04475120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC therapy
Description: oral administration
Study NCT03698227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: iv infusion
Study NCT03698227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: iv infusion
Study NCT03698227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: iv infusion
Study NCT00913419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories
Study NCT00913419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme
Study NCT03660761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: The patient was given a daily dose of apatinib 500mg (or based on weight). For adult, the dose of apatinib was prescribed with 425 mg or 500 mg per day and four weeks for a cycle. The dosage was modified to 250 mg if patients experienced ≧grade 2 hematologic adverse events, hand and foot syndrome, proteinuria, fecal ocular blood, or grade 3/4 hypertension, or other grade 3/4 adverse events. Apatinib was administrated until disease progression, unacceptable toxicity or death.
Study NCT03660761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temodar
Description: dose-dense temozolomide (100 mg/m2 , 7 days on with 7 days off ) , 28d
Study NCT03826069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented reality-based curriculum
Description: Participants in the Augmented Reality Group will be taught principles in augmented reality and training sessions will be enhanced by an augmented reality platform. This involves training on virtual reality simulators with superimposed videos and guides demonstrating correct procedure. In this study, the videos and guides will be on identifying and removing polyps.
Study NCT03826069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Simulation Curriculum
Description: Participants in this group will will train from low- to high-fidelity colonoscopy simulation. During training, the participants will receive guidance and feedback from expert endoscopists. In addition, there will be didactic sessions covering theory of colonoscopy.
Study NCT04678635 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Chronic transcranial direct current stimulation
Description: Chronic transcranial direct current stimulation
Study NCT04678635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chronic transcranial direct current stimulation
Description: Chronic transcranial direct current stimulation
Study NCT00583063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: 25 mg daily (oral dosing)
Study NCT00583063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rapamycin
Description: 4 mg daily (oral dosing)
Study NCT00752479 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells infusion, Basiliximab,Methylprednisolone,RATG ,Cyclosporine ,Mycophenolate mofetil
Description: Cell therapy~Mesenchymal cells infusion.~Induction therapy:~Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).~Maintenance therapy:~Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx).
Study NCT00752479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab, Methylprednisolone,RATG,Cyclosporine,Mycophenolate mofetil
Description: Routine immunosuppressive therapy~Induction therapy:~Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).~Maintenance therapy:~Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx).
Study NCT03782363 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CIK Dose level 1
Description: Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 20.000.000 cell/kgs days 1 and 22
Study NCT03782363 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CIK Dose level 2
Description: Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 25.000.000 cell/kgs days 1 and 22
Study NCT03782363 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CIK Dose level 3
Description: Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 20.000.000 cell/kgs days 1 and 15
Study NCT03782363 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CIK Dose level 4
Description: Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 25.000.000 cell/kgs days 1 and 15
Study NCT03124576 — intervention group
Intervention type: DEVICE
Intervention: Implantable loop recorder
Description: Continuous rhythm monitoring Medtronic
Study NCT01622673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 400 mg oral tablet taken with 240 mL water every 12 hours~Throughout the study, participants will continue to take raltegravir along with their other HIV medications. On the day of co-dosing and intensive pharmacokinetic (PK) sampling, raltegravir will be dosed in the morning in a fasted state in all periods.
Study NCT01979952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: twice daily dosing
Study NCT01979952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: gelating capsule
Study NCT03502447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TearCare
Description: TearCare treatment includes an in-office 15 minute thermal treatment session where heat is delivered to the eyelids. This is immediately followed by manual clearing of the meibomian glands.
Study NCT03502447 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Warm Compress and Lid Massage
Description: Subjects randomized to the Warm Compress and Lid Massage Group will be instructed to apply a moist, warm compress to their eyelids daily for 5 minutes and then perform lid massage.
Study NCT03793361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Oral Drug in the form of 40 mg tablets - Regorafenib (120 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.~Provided by BAYER
Study NCT01622673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TUMS® Ultra Strength
Description: 3 tablets TUMS® Ultra Strength (US) 1000 mg~Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods.
Study NCT03793361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets - Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression~Provided by BAYER
Study NCT03000829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-intensivist consultation
Description: Standardized consultation to on-site cardiac arrest team by off-site intensivist via two-way audiovisual link using a mobile telemedicine cart
Study NCT03000829 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Simulated observation by ICU physician
Description: Display of silent, pre-recorded, non-interactive videotape of an ICU physician. The on-site cardiac arrest team will be told that an intensive care physician is observing the mock code.
Study NCT02682316 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dry gauze
Study NCT02682316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Prevena Incision Management System
Study NCT04257812 — intervention group
Intervention type: DRUG
Intervention: Ceftolozane/tazobactam
Description: The dose will be 1g ceftolozane + 0,5 g tazobactam every 8 hours or 2 g ceftolozane + 1 g tazobactam, it´s recommended to use this last dose regimen in patients with pneumonia or septic shock of any focus.~The patients will be followed as it´s done habitually. There will be done infection focus cultures and others according to usual clinical practice. It´ll be determined the clinical response and mortality in the days 14 and 30 after the beginning of the medicine, respectively.~The Ceftolozane-Tazobactam levels determination will always be made in state of equilibrium (after the third dose). Four samples will be collected:~1. Just before the antibiotic infusion.~2. One hour after the antibiotic infusion.~3. Three hours after the antibiotic infusion.~4. Six hours after the antibiotic infusion.
Study NCT04914728 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mini-invasive lumbar arthrodesis
Description: * The mini-invasive posterior approach is performed using a trans-muscular Wiltse approach. Pedicle screws, neurological decompression and intersomatic cage placement are performed.~* The mini-invasive anterior approach is performed via a left retroperitoneal pararectal approach. After complete discectomy, an intersomatic cage stabilised by a screwed plate will be placed.
Study NCT01489969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neu-P11
Description: 1 tablet daily 1-2 before bed time for 28 days of double blind treatment
Study NCT01489969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neu-P11
Description: 1 tablet daily 1-2 before bed time for 28 days of double blind treatment
Study NCT00267865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 6000 mg/m\^2 will be administered by intravenous infusion over 4 hours after confirming that the recipient patients urine pH is within the range greater than or equal to 7 to less than or equal to 8, and urine output is greater than or equal to 100 mL/hour.
Study NCT00267865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 intravenous (IV) day 1 of each cycle prior to administration of high-dose methotrexate
Study NCT00267865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin calcium doses will be administered orally or by short intravenous (IV) infusion over 15 minutes
Study NCT01715818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching aleglitazar placebo tablet orally daily
Study NCT01715818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: 150 mcg orally daily
Study NCT02347566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity enhancing programme
Description: COPD patients performing pulmonary rehabilitation will wear the DirectLife activity monitor with set targets and feedback. They will have access to a web coaching programme. Their physical activity targets will be updated on a weekly basis in order to enhance their physical activity.
Study NCT02347566 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: COPD patients performing pulmonary rehabilitation will wear the DirectLife activity monitor without set targets and/or feedback. They will not have access to a web coaching programme.